The phase II ARC-7 study investigated the addition of the novel antibody domvanalimab to immunotherapy for patients with stage IV non–small cell lung cancer (NSCLC). Results were presented by Johnson et al during the December 2022 session of the ASCO Plenary Series (Abstract 397600).
